Telmisartan Randomised Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease - TRANSCEND


The goal of this trial was to assess whether the long-term use of telmisartan, an angiotensin-receptor blocker (ARB), is associated with a reduction in cardiovascular endpoints in patients with cardiovascular disease or high-risk diabetes and without heart failure, who are intolerant to angiotensin-converting enzyme (ACE) inhibitors, when compared with placebo, in addition to usual therapies.